Safety Reporting in Medical Device Clinical Trials: US IDE, EU MDR & ISO 14155

In medical device clinical investigations, safety reporting is the sponsor's and investigator's most time-sensitive legal duty. When an adverse event occurs during a trial under a U.S. Investigational Device Exemption (IDE) or a European Union Medical Device Regulation (EU MDR 2017/745) clinical investigation, clinical operations and medical affairs teams must navigate complex, multi-tiered reporting clocks. Missing these windows jeopardizes subject safety and exposes sponsors to termination or disapproval of the IDE, rejection of pivotal data during PMA or CE-mark reviews, and warning letters from regulatory enforcement bodies.

Yet, safety reporting in medical device trials is routinely mismanaged because clinical research teams frequently import rules from two adjacent domains:

1. Pharmaceutical Clinical Trials: Applying drug-trial rules (such as 7-day or 15-day IND Suspected Unexpected Serious Adverse Reaction / SUSAR timelines under 21 CFR 312.32 or the EU Clinical Trials Regulation CTR 536/2014) to medical devices.
2. Postmarket Surveillance: Conflating investigational reporting with commercial 21 CFR Part 803 Medical Device Reporting (MDR) or EU postmarket vigilance under MDR Articles 87–90.

Medical device trials operate under an entirely distinct statutory regime. In the U.S., safety reporting centers on the Unanticipated Adverse Device Effect (UADE) under 21 CFR Part 812, governed by a pair of 10-working-day clocks. In the EU, safety reporting is governed by MDR Article 80, where the legal statute mandates reporting "without delay" while the operational 2-calendar-day and 7-calendar-day deadlines derive from MDCG 2020-10/1 Rev.1 guidance.

Disambiguation Note: This guide covers in-trial safety reporting during investigational medical device studies under Good Clinical Practice (GCP). It does not cover postmarket adverse event reporting for commercially cleared or approved devices under 21 CFR Part 803 (FDA MDR), postmarket European vigilance under EU MDR Articles 87–90, protocol modification approvals covered in our protocol deviations guide, data safety monitoring board mandates in our DSMB / DMC guide, or independent endpoint adjudication by a Clinical Events Committee (CEC).

Direct Answer: If an unexpected serious injury occurs at a trial site today during a pivotal device study running across U.S. IDE and EU MDR Article 62 sites:

• In the United States (21 CFR 812.150): The investigator must submit a UADE report to the sponsor and the reviewing Institutional Review Board (IRB) as soon as possible, but in no event later than 10 working days after first learning of the effect (21 CFR 812.150(a)(1)). The sponsor must evaluate the UADE immediately (21 CFR 812.46(b)) and submit an evaluation report to the FDA, all reviewing IRBs, and all participating investigators within 10 working days of first receiving notice (21 CFR 812.150(b)(1)).
• In the European Union (MDR Article 80 & MDCG 2020-10/1 Rev.1): The investigator must report the event to the sponsor immediately and no later than 3 calendar days from awareness. The sponsor must report serious adverse events (SAEs) with a possible or confirmed causal relationship, as well as device deficiencies that might have led to an SAE, to all National Competent Authorities (NCAs) where the investigation is conducted. The deadline is immediately, and no later than 2 calendar days if the event indicates an imminent risk requiring prompt remedial action, or no later than 7 calendar days for all other reportable events.
• EUDAMED Status (as of 2026): Because the EUDAMED Clinical Investigations and Performance Studies (CI/PS) module is not yet mandatory (four other modules became mandatory on 28 May 2026 under Commission Decision (EU) 2025/2371), EU safety reports do not go through an automated central portal today. Instead, sponsors must submit the MDCG 2020-10/2 Rev.1 Clinical Investigation Summary Safety Report Form directly to each national competent authority via national portals or secure email.

---

What Events Trigger a Safety Report in a US Device Investigation?

Under U.S. FDA regulations governing Investigational Device Exemptions (21 CFR Part 812), the regulatory trigger for expedited safety reporting is not simply a "serious adverse event" (a drug concept), but an Unanticipated Adverse Device Effect (UADE).

+----------------------------------------------------------------------------------------------------+
|                      21 CFR 812.3(s) UADE DEFINITION: THE THREE-PRONG TEST                         |
+----------------------------------------------------------------------------------------------------+
|                                                                                                    |
|  [ PRONG 1: SEVERITY ]                                                                             |
|  Any serious adverse effect on health or safety, or any life-threatening problem or death          |
|                                                                                                    |
|                                 AND                                                                |
|                                                                                                    |
|  [ PRONG 2: CAUSALITY / ASSOCIATION ]                                                              |
|  Caused by, or associated with, a device                                                           |
|                                                                                                    |
|                                 AND                                                                |
|                                                                                                    |
|  [ PRONG 3: UNANTICIPATED NATURE ]                                                                 |
|  Not previously identified in nature, severity, or degree of incidence in the investigational      |
|  plan or application (including a supplementary plan or application)                               |
|                                                                                                    |
|  -- OR --                                                                                          |
|                                                                                                    |
|  [ ALTERNATIVE TRIGGER ]                                                                           |
|  Any other unanticipated serious problem associated with a device that relates to the rights,      |
|  safety, or welfare of subjects.                                                                   |
|                                                                                                    |
+----------------------------------------------------------------------------------------------------+

Statutory Definition (21 CFR 812.3(s))

As codified in 21 CFR 812.3(s), an Unanticipated Adverse Device Effect is defined verbatim as:

"any serious adverse effect on health or safety or any life-threatening problem or death caused by, or associated with, a device, if that effect, problem, or death was not previously identified in nature, severity, or degree of incidence in the investigational plan or application (including a supplementary plan or application), or any other unanticipated serious problem associated with a device that relates to the rights, safety, or welfare of subjects."

Anticipated vs. Unanticipated Events

Understanding what is "anticipated" is critical to avoid under-reporting or unnecessary panic:

• Anticipated serious adverse device effects: Complications that are documented in the Investigator's Brochure (IB), risk management file (ISO 14971), and Clinical Investigation Plan (CIP) with an estimated frequency. For example, a 2% rate of vascular access site hematoma in a catheter trial is anticipated. If a subject experiences this hematoma within the expected severity and frequency, it is recorded in the electronic Case Report Form (eCRF) and included in annual progress reports, but it does not trigger an immediate 10-working-day UADE report.
• When an Anticipated Event Becomes Unanticipated: An event becomes a UADE if its nature (e.g., unusual tissue necrosis instead of standard hematoma), severity (e.g., fatal hemorrhage requiring emergency bypass rather than localized hematoma), or degree of incidence (e.g., hematoma observed in 12% of patients when the protocol predicted 2%) exceeds what was identified in the approved investigational plan.

Who Assesses UADE Status? (FDA December 2025 Final Guidance)

In December 2025, the FDA finalized its comprehensive cross-center guidance, Investigator Responsibilities — Safety Reporting for Investigational Drugs and Devices (Docket FDA-2021-D-0368, issued with the participation of CDRH, CDER, CBER, and the Oncology Center of Excellence). This guidance formally withdrew both the 2012 drug-oriented IND guidance and the 2009 adverse-event-to-IRB guidance, consolidating device trial expectations in Section VII.

The December 2025 guidance clarifies two pivotal principles regarding assessment authority:

1. The Sponsor is Better Positioned for Aggregate Analysis: Individual investigators observe only a fraction of enrolled subjects and cannot reliably determine whether a single event represents a broader safety signal or exceeds the expected degree of incidence. Therefore, investigators must notify the sponsor of any serious, unexpected adverse event potentially linked to the device, while the sponsor holds the regulatory duty to conduct the definitive UADE evaluation across all trial sites.
2. Handling Disagreements Between Investigator and Sponsor: If an investigator evaluates an event as a UADE but the sponsor's medical monitor concludes it is unrelated or anticipated, the sponsor's evaluation governs what is reported to FDA, reviewing IRBs, and other trial sites: 21 CFR 812.46(b) and 812.150(b)(1) place the evaluation and reporting duties on the sponsor, and the December 2025 guidance adds that the sponsor should carefully consider the investigator's assessment of causality even though the final determination rests with the sponsor. Neither the regulation nor the guidance prescribes what to do when the two assessments diverge, so SOPs should follow standard GCP documentation practice under ISO 14155 — record both the investigator's original assessment and the sponsor's rationale in the safety file and Trial Master File (TMF) — and investigators should remember that their reviewing IRB's written procedures can impose additional local reporting obligations on top of 21 CFR 812.150(a)(1).

---

Who Reports UADEs to FDA, IRBs, and Investigators, and on Which Clock?

Safety reporting under 21 CFR 812.150 operates as a two-tiered relay between the investigator, the sponsor, the reviewing IRBs, and the FDA.

+----------------------------------------------------------------------------------------------------+
|                         US IDE SAFETY REPORTING RELAY (21 CFR 812.150)                             |
+----------------------------------------------------------------------------------------------------+
|                                                                                                    |
|  [ EVENT OCCURS AT SITE ]                                                                          |
|  Subject experiences unexpected serious adverse event or life-threatening complication             |
|                                                                                                    |
|                                 |                                                                  |
|                                 |  INVESTIGATOR CLOCK: <= 10 Working Days (21 CFR 812.150(a)(1))   |
|                                 v                                                                  |
|                                                                                                    |
|  +----------------------------------------------------------------------------------------------+  |
|  |  INVESTIGATOR NOTIFIES:                                                                      |  |
|  |  1. Sponsor (immediate alert + full UADE documentation)                                      |  |
|  |  2. Reviewing IRB (duplicate-copy relief possible only under a documented      |  |
|  |     agreement -- see Section 1 caveat below)                                   |  |
|  +----------------------------------------------------------------------------------------------+  |
|                                                                                                    |
|                                 |                                                                  |
|                                 |  SPONSOR EVALUATION: Immediate (21 CFR 812.46(b))                |
|                                 |  SPONSOR REPORT CLOCK: <= 10 Working Days (21 CFR 812.150(b)(1)) |
|                                 v                                                                  |
|                                                                                                    |
|  +----------------------------------------------------------------------------------------------+  |
|  |  SPONSOR SUBMITS EVALUATION REPORT TO:                                                       |  |
|  |  1. Food and Drug Administration (CDRH / CBER IDE Document Control Center)                   |  |
|  |  2. All Reviewing IRBs across all active investigational sites                              |  |
|  |  3. All Participating Investigators across all trial sites                                   |  |
|  +----------------------------------------------------------------------------------------------+  |
|                                                                                                    |
|                                 |                                                                  |
|                                 |  IF UADE PRESENTS UNREASONABLE RISK (21 CFR 812.46(b)(2))        |
|                                 v                                                                  |
|                                                                                                    |
|  +----------------------------------------------------------------------------------------------+  |
|  |  SPONSOR TERMINATES STUDY:                                                                   |  |
|  |  - As soon as possible, <= 5 working days after determination                                 |  |
|  |  - No later than 15 working days after first receiving notice of effect                      |  |
|  |  - Cannot resume significant risk study without IRB and FDA approval (812.46(c))             |  |
|  +----------------------------------------------------------------------------------------------+  |
|                                                                                                    |
+----------------------------------------------------------------------------------------------------+

1. The Investigator Reporting Duty (21 CFR 812.150(a)(1))

Under 21 CFR 812.150(a)(1):

• Recipient: The investigator must report any UADE to the sponsor and to the reviewing IRB.
• Timeline: "as soon as possible, but in no event later than 10 working days after the investigator first learns of the effect."
• Documented-Agreement Relief (December 2025 Guidance, Footnote 18): Footnote 18 of the December 2025 guidance states that where an agreement specifies the sponsor will submit safety reports to the IRB on the investigator's behalf, and the investigator receives confirmation that the report was sent, FDA would not expect the investigator to provide the IRB with a duplicate copy. FDA frames this in the IND context (investigator reports to IRBs under 21 CFR 312.66); the guidance does not repeat an express IDE analog, so sponsors applying the same arrangement to UADE reports under 812.150(a)(1) should confirm that each reviewing IRB accepts sponsor-submitted reports and should document the agreement in writing.

2. The Sponsor Evaluation and Distribution Duty (21 CFR 812.46(b) & 812.150(b)(1))

Under 21 CFR 812.46(b) and 21 CFR 812.150(b)(1):

• Evaluation: The sponsor must immediately conduct an evaluation of the UADE.
• Reporting Timeline: The sponsor must submit the results of the evaluation to the FDA, all reviewing IRBs, and all participating investigators within 10 working days after first receiving notice of the effect.
• All-Investigator Notification: A frequent compliance failure is notifying only the site that experienced the event. Section 812.150(b)(1) strictly mandates notification of all participating investigators across the entire study so that clinicians at other sites can monitor their enrolled subjects for similar emerging risks.

3. Study Termination for Unreasonable Risk (21 CFR 812.46(b)(2))

If the sponsor's evaluation determines that the UADE presents an unreasonable risk to subjects, the sponsor must terminate the investigation or parts of the investigation:

• Termination Clock: As soon as possible, and no later than 5 working days after making that determination.
• Absolute Ceiling: In no event later than 15 working days after the sponsor first received notice of the UADE.
• Resumption Controls (21 CFR 812.46(c)): If a Significant Risk (SR) study is terminated under this section, the sponsor cannot resume the study without approval from both the reviewing IRB and the FDA.

The Complete 21 CFR 812.150 Clock Inventory

Beyond UADE reporting, 21 CFR 812.150 establishes several mandatory reporting clocks that clinical operations teams frequently overlook:

Trigger Event	Responsible Party	Recipient	Regulatory Clock	CFR Citation
UADE Occurrence	Investigator	Sponsor & Reviewing IRB	≤ 10 working days from awareness	21 CFR 812.150(a)(1)
UADE Evaluation Results	Sponsor	FDA, all IRBs, all Investigators	≤ 10 working days from notice	21 CFR 812.150(b)(1)
Unreasonable Risk Termination	Sponsor	FDA, all IRBs, all Investigators	≤ 5 working days from decision (≤ 15 working days from notice)	21 CFR 812.46(b)(2)
Emergency Protocol Deviation (to protect life/well-being)	Investigator	Sponsor & Reviewing IRB	≤ 5 working days from deviation	21 CFR 812.150(a)(4)
Withdrawal of IRB Approval	Investigator	Sponsor	≤ 5 working days from notification	21 CFR 812.150(a)(2)
Withdrawal of IRB Approval	Sponsor	FDA, all Reviewing IRBs & Investigators	≤ 5 working days from notice	21 CFR 812.150(b)(2)
Withdrawal of FDA Approval	Sponsor	All Reviewing IRBs & Investigators	≤ 5 working days from notice	21 CFR 812.150(b)(3)
Device Use Without Informed Consent	Investigator	Sponsor & Reviewing IRB	≤ 5 working days from use	21 CFR 812.150(a)(5)
Device Use Without Informed Consent	Sponsor	FDA	≤ 5 working days from notice	21 CFR 812.150(b)(8)
IRB Significant Risk (SR) Determination (overriding NSR plan)	Sponsor	FDA	≤ 5 working days from notice	21 CFR 812.150(b)(9)
Current Investigator List	Sponsor	FDA	Every 6 months	21 CFR 812.150(b)(4)
Progress Reports (SR Study)	Sponsor	FDA & all Reviewing IRBs	At least yearly	21 CFR 812.150(b)(5)
Progress Reports (NSR Study)	Sponsor	All Reviewing IRBs	At least yearly	21 CFR 812.150(b)(5)
Investigator Final Report	Investigator	Sponsor & Reviewing IRB	≤ 3 months from completion or termination	21 CFR 812.150(a)(6)
Device Return / Repair / Disposition Request	Sponsor	FDA & all Reviewing IRBs	≤ 30 working days after request	21 CFR 812.150(b)(6)
SR Study Completion / Termination Notice	Sponsor	FDA	≤ 30 days from completion or termination	21 CFR 812.150(b)(7)
Final Investigation Report	Sponsor	FDA, all IRBs, all Investigators	≤ 6 months from completion	21 CFR 812.150(b)(7)

---

What Are the EU MDR Article 80 Duties, and Where Do the Real Deadlines Come From?

In the European Union, safety reporting during clinical investigations conducted under Regulation (EU) 2017/745 (MDR) Article 62 or Article 74(2) is governed by Article 80.

+----------------------------------------------------------------------------------------------------+
|                         EU MDR ARTICLE 80 SAFETY REPORTING ARCHITECTURE                             |
+----------------------------------------------------------------------------------------------------+
|                                                                                                    |
|  [ MDR ARTICLE 80(1): INVESTIGATOR RECORDING & REPORTING ]                                         |
|  Investigator records all adverse events & device deficiencies; reports reportable events to       |
|  sponsor immediately (no later than 3 calendar days per MDCG 2020-10/1 Rev.1).                     |
|                                                                                                    |
|                                 |                                                                  |
|                                 v                                                                  |
|                                                                                                    |
|  [ MDR ARTICLE 80(2): SPONSOR REPORTING DUTY ("WITHOUT DELAY") ]                                   |
|  Sponsor must report to ALL Member States where study is active:                                   |
|  (a) Serious Adverse Events (SAEs) with causal (or reasonably possible) link to device,           |
|      comparator, or investigational procedure.                                                     |
|  (b) Device Deficiencies that might have led to an SAE if no action/intervention taken.             |
|  (c) Any new findings regarding reported events.                                                   |
|                                                                                                    |
|                                 |                                                                  |
|                                 v                                                                  |
|                                                                                                    |
|  [ OPERATIONAL DEADLINES: MDCG 2020-10/1 REV.1 GUIDANCE ]                                         |
|                                                                                                    |
|  +----------------------------------------------------------------------------------------------+  |
|  |  IMMINENT RISK EVENT:                                                                        |  |
|  |  Event indicating imminent risk of death, serious injury, or serious illness requiring       |  |
|  |  prompt remedial action -> <= 2 CALENDAR DAYS after sponsor awareness                        |  |
|  +----------------------------------------------------------------------------------------------+  |
|  |  ALL OTHER REPORTABLE EVENTS:                                                                |  |
|  |  All other reportable SAEs, device deficiencies, or new follow-up information ->             |  |
|  |  <= 7 CALENDAR DAYS after sponsor awareness                                                  |  |
|  +----------------------------------------------------------------------------------------------+  |
|                                                                                                    |
+----------------------------------------------------------------------------------------------------+

1. Legal Scope of MDR Article 80

Under Article 80(2), the sponsor must report:

1. Any Serious Adverse Event (SAE) that has a causal relationship with the investigational device, an active comparator, or the investigation procedure—or where such a causal relationship is reasonably possible.
2. Any Device Deficiency that might have led to a serious adverse event if appropriate action had not been taken, if intervention had not occurred, or if circumstances had been less fortunate.
3. Any new findings in relation to any previously reported event.

2. The Law vs. Guidance Distinction: Where Do the Day Counts Come From?

A critical legal distinction exists that many regulatory professionals miss:

• The MDR Text (Statute): Article 80(2) contains no numerical day counts. The regulation states only that reporting must occur "without delay" and that "the period for reporting shall take account of the severity of the event."
• MDCG 2020-10/1 Rev.1 (Guidance): The specific deadlines of 2 calendar days and 7 calendar days derive from guidance issued by the Medical Device Coordination Group in MDCG 2020-10/1 Rev.1 — Safety reporting in clinical investigations (October 2022).

While MDCG documents are legally non-binding guidance documents in EU jurisprudence, National Competent Authorities (NCAs) across EU Member States (such as BfArM in Germany, ANSM in France, CCMO in the Netherlands, and MPA in Sweden) enforce MDCG 2020-10/1 Rev.1 timelines as the standard of compliance. Failure to meet these deadlines can lead to formal NCA inquiries and suspension of the investigation.

3. EUDAMED Reality Check: The Interim Reporting Workaround

Article 80(2) specifies that safety reports shall be submitted electronically via the system referred to in Article 73 (EUDAMED). However, clinical teams must understand the current transitional reality:

• Under Commission Decision (EU) 2025/2371, four core EUDAMED modules became mandatory on 28 May 2026 (Actor Registration, UDI & Device Registration, Notified Bodies & Certificates, and Market Surveillance).
• However, the Clinical Investigations and Performance Studies (CI/PS) module and the Vigilance module remain under development and do not have a mandatory or voluntary submission mechanism active today.
• The Current Procedure: In the absence of an operational EUDAMED CI/PS module, sponsors must follow the national procedure outlined in MDCG 2020-10/1 Rev.1 Section 1.1:
  • Sponsors complete the standardized MDCG 2020-10/2 Rev.1 Clinical Investigation Summary Safety Report Form (a standardized tabular reporting form).
  • The form must be transmitted to the National Competent Authority of every Member State in which the clinical investigation is being conducted, using each country's designated portal or secure submission email (e.g., the CCMO Research Portal in the Netherlands or the DMP portal in Norway).

+----------------------------------------------------------------------------------------------------+
|                         EUDAMED MODULE TRANSITION STATUS (AS OF 2026)                              |
+----------------------------------------------------------------------------------------------------+
|  MODULE 1: Actor Registration                   | MANDATORY (Since 28 May 2026)                    |
|  MODULE 2: UDI & Device Registration            | MANDATORY (Since 28 May 2026)                    |
|  MODULE 3: Notified Bodies & Certificates       | MANDATORY (Since 28 May 2026)                    |
|  MODULE 4: Market Surveillance                  | MANDATORY (Since 28 May 2026)                    |
|  MODULE 5: Clinical Investigations (CI/PS)     | UNDER DEVELOPMENT (Interim National Submission)  |
|  MODULE 6: Vigilance & Postmarket Surveillance  | UNDER DEVELOPMENT (National Workarounds)         |
+----------------------------------------------------------------------------------------------------+

4. The PMCF Carve-Out: Article 80 vs. Postmarket Vigilance

A common source of confusion is safety reporting in Post-Market Clinical Follow-up (PMCF) studies and other investigations of CE-marked devices. MDR Article 80(5) and 80(6) establish a split regime, and which regime applies depends on how the CE-marked device is used (per MDCG 2020-10/1 Rev.1 sections 2.1 and 5.1):

• CE-Marked Device Used Within Intended Purpose, With Additional Invasive or Burdensome Procedures (Article 74(1)): SAE reporting is governed by Articles 80(5) and 80(6) operating together. Serious adverse events relating to the device itself follow the vigilance provisions of Articles 87 to 90, reported through the postmarket manufacturer pathway. However, an SAE with an established causal relationship to a preceding investigational procedure — defined by MDCG 2020-10/1 Rev.1 as a procedure imposed by the clinical investigation plan that took place before (or coincided with) the event, including the investigational device application procedure and any additional invasive or burdensome procedures — must be reported via the Article 80 clinical investigation pathway (e.g., an extra biopsy or arterial puncture mandated by the study protocol). MDCG 2020-10/1 Rev.1 section 5.1 adds two traps: in these studies, "possible" and "probable" causality do not trigger Article 80 reporting (only established causality does), and a single event can be reportable through both the investigation pathway and vigilance at the same time.
• CE-Marked Device Used Outside Its Intended Purpose (Article 74(2)): Treated like a pre-market Article 62 investigation: Article 80 applies in full, with reportable SAEs, device deficiencies, and new findings subject to the MDCG 2/7-calendar-day clocks described above.
• CE-Marked Device Within Intended Purpose, No Additional Procedures (e.g., "pure" PMCF): These studies sit outside the Article 80 regime altogether. MDCG 2020-10/1 Rev.1's scope table points them to MDR Chapter VII post-market surveillance and vigilance duties, and member-state law may add notification requirements — check with each National Competent Authority.

---

Recommended Reading

Imaging Core Labs for Medical Device Clinical Trials: FDA Expectations and Setup Guide

Clinical Evidence Regulatory2026-08-15 · 33 min read

The Standards Layer: ISO 14155 GCP Harmonization

Beyond statutory regulations, clinical device investigations must comply with international Good Clinical Practice. The global gold standard is ISO 14155 (Clinical investigation of medical devices for human subjects — Good clinical practice).

+----------------------------------------------------------------------------------------------------+
|                      ISO 14155 SAFETY TERMINOLOGY & HARMONIZATION STATUS                           |
+----------------------------------------------------------------------------------------------------+
|                                                                                                    |
|  [ HARMONIZATION STATUS (COMMISSION IMPLEMENTING DECISION (EU) 2026/193) ]                         |
|  - Harmonized EN ISO 14155:2020 and EN ISO 14155:2020/A11:2024 under EU MDR (dated 28 Jan 2026)    |
|  - ISO 14155:2026 (fourth edition, March 2026) supersedes 2020 edition globally; its European     |
|    harmonization in the Official Journal (OJ) is currently pending.                                |
|                                                                                                    |
|  [ CORE SAFETY DEFINITIONS ]                                                                       |
|  * Adverse Event (AE): Any untoward medical occurrence in a subject (no causal link required).     |
|  * Adverse Device Effect (ADE): Adverse event related to the use of an investigational device.     |
|  * Serious Adverse Event (SAE): AE leading to death, serious deterioration in health, or fetal     |
|    distress / congenital abnormality.                                                              |
|  * Serious Adverse Device Effect (SADE): ADE resulting in any of the consequences of an SAE.       |
|  * Unanticipated SADE (USADE): Serious adverse device effect which by its nature, incidence,       |
|    severity or outcome has not been identified in the current risk assessment.                     |
|  * Device Deficiency (DD): Inadequacy of medical device with respect to identity, quality,         |
|    durability, reliability, safety or performance (includes malfunctions and user errors).         |
|                                                                                                    |
+----------------------------------------------------------------------------------------------------+

Harmonization Status

• Decision (EU) 2026/193: On 28 January 2026, the European Commission adopted Commission Implementing Decision (EU) 2026/193 (published in the Official Journal on 30 January 2026), officially adding EN ISO 14155:2020 and its amendment EN ISO 14155:2020/A11:2024 to the list of harmonized standards under Regulation (EU) 2017/745.
• ISO 14155:2026 Fourth Edition: In March 2026, ISO published the fourth edition (ISO 14155:2026), which cancels and replaces the 2020 edition with no transition period. The fourth edition modernizes safety workflows by establishing risk-proportionate monitoring approaches (including remote and centralized monitoring), formal Data Monitoring Committee (DMC) and Clinical Events Committee (CEC) governance, mandatory risk-management integration aligned with ISO 14971, and an estimand framework aligned with ICH E9(R1). Sponsors should design global SOPs to meet ISO 14155:2026 standards while referencing EN ISO 14155:2020/A11:2024 for EU MDR presumption of conformity.

---

US vs. EU Safety Reporting Compared: The Working vs. Calendar Days Trap

When operating a multi-center pivotal trial across U.S. and European sites, standard operating procedures must reconcile two fundamentally different timekeeping systems.

+----------------------------------------------------------------------------------------------------+
|                         THE CRITICAL TIMEKEEPING UNIT TRAP: US VS EU                               |
+----------------------------------------------------------------------------------------------------+
|                                                                                                    |
|  SCENARIO: Site becomes aware of a serious unexpected injury at 4:30 PM on Friday, October 2nd.    |
|                                                                                                    |
|  [ UNITED STATES: 21 CFR 812.150 ]                                                                 |
|  * Time Unit: "WORKING DAYS" (Excludes Saturdays, Sundays, and Federal Holidays)                   |
|  * 10 Working Days = Approximately 14 to 16 CALENDAR DAYS.                                         |
|  * Deadline for Sponsor Submission: Monday, October 19th.                                          |
|                                                                                                    |
|  [ EUROPEAN UNION: MDCG 2020-10/1 REV.1 ]                                                          |
|  * Time Unit: "CALENDAR DAYS" (Includes all weekends and public holidays)                          |
|  * Imminent Risk (2 Calendar Days) = Sunday, October 4th (48 hours).                               |
|  * Standard Reportable Event (7 Calendar Days) = Friday, October 9th.                              |
|                                                                                                    |
|  CRITICAL TAKEAWAY: The EU 7-day clock expires a full 10 CALENDAR DAYS BEFORE the US 10-day clock! |
|                                                                                                    |
+----------------------------------------------------------------------------------------------------+

Side-by-Side Comparison Matrix

Feature	United States (21 CFR Part 812)	European Union (MDR Art. 80 & MDCG 2020-10)	ISO 14155 GCP Global Standard
Primary Safety Trigger	Unanticipated Adverse Device Effect (UADE)	Reportable SAE (related/possibly related) & Device Deficiencies	Unanticipated Serious Adverse Device Effect (USADE) & DDs
Investigator → Sponsor Clock	≤ 10 working days from awareness (812.150(a)(1))	Immediately, ≤ 3 calendar days from awareness (MDCG)	Without delay, per CIP / protocol specifications
Sponsor Evaluation Duty	Immediate evaluation (812.46(b))	Immediate causal & severity assessment	Formal causal assessment with Principal Investigator
Sponsor → Regulator Clock	≤ 10 working days from receiving notice (812.150(b)(1))	≤ 2 calendar days (imminent risk) / ≤ 7 calendar days (standard)	Without delay / per national regulatory requirements
Sponsor → Ethics / IRB Clock	≤ 10 working days to all reviewing IRBs	National rules (simultaneous with NCA in most Member States)	Per Ethics Committee approval conditions
Sponsor → Other Investigators	≤ 10 working days to all participating investigators	Follows national GCP guidelines and sponsor safety updates	Promptly inform all participating investigators
Device Deficiency Reporting	Deficiencies reported only if meeting UADE or deviation criteria	Mandatory to report if deficiency might have led to an SAE	Mandatory to document and report potential-SAE deficiencies
Legal Basis of Timelines	Federal Regulation (21 CFR Part 812)	Guidance (MDCG 2020-10/1 Rev.1) interpreting MDR statute	International voluntary standard / Harmonized standard
Submission Portal / Channel	FDA CDRH/CBER Document Control Center	National Competent Authority portals (EUDAMED CI module pending)	National portals / secure regulatory transmissions

---

Disambiguation: Investigational Safety vs. Postmarket MDR vs. Drug SUSARs

A major source of regulatory noncompliance is applying the wrong reporting framework to the wrong stage of a product lifecycle.

+----------------------------------------------------------------------------------------------------+
|                         SAFETY REPORTING REGIME DISAMBIGUATION                                     |
+----------------------------------------------------------------------------------------------------+
|                                                                                                    |
|  [ 1. INVESTIGATIONAL DEVICE SAFETY (21 CFR PART 812 / MDR ART. 80) ]                              |
|  - Applies to: Unapproved devices or new indications under an active clinical trial.               |
|  - Triggers: UADEs, reportable SAEs, reportable device deficiencies.                               |
|  - Clocks: 10 working days (US); 2 or 7 calendar days (EU).                                         |
|  - Focus: Protecting enrolled clinical trial subjects and assessing protocol risk.                 |
|                                                                                                    |
|  [ 2. POSTMARKET MEDICAL DEVICE REPORTING (21 CFR PART 803 / MDR ART. 87-90) ]                     |
|  - Applies to: Commercially distributed devices in routine clinical use.                           |
|  - Triggers: Device-related deaths, serious injuries, and recurring malfunctions.                  |
|  - Clocks: 30 calendar days (standard MDR); 5 work days (remedial action / FDA request).          |
|  - Submission: FDA Form 3500A (eMDR) / Manufacturer Incident Report (MIR) to NCAs.                |
|                                                                                                    |
|  [ 3. INVESTIGATIONAL DRUG SAFETY (21 CFR 312.32 / CTR 536/2014) ]                                 |
|  - Applies to: Investigational New Drugs (INDs) and pharmaceutical clinical trials.                |
|  - Triggers: Suspected Unexpected Serious Adverse Reactions (SUSARs).                              |
|  - Clocks: 7 calendar days (fatal/life-threatening); 15 calendar days (all other SUSARs).          |
|  - Mechanism: CIOMS-I forms / EudraVigilance Clinical Trial Module.                               |
|                                                                                                    |
+----------------------------------------------------------------------------------------------------+

The Dual-Status Device Dilemma

What happens when a medical device is already cleared (e.g., via 510(k)) for Indication A, but is currently being studied under an IDE for Indication B?

• Events Occurring Within the IDE Study: Any adverse event occurring in a subject enrolled in the IDE study must be evaluated and reported under 21 CFR Part 812 safety reporting rules.
• Events Occurring in Commercial Distribution: Complaints and adverse events arising from commercial clinical use of the cleared device outside the trial must be reported under 21 CFR Part 803 postmarket MDR rules.
• Cross-Contamination Risk: If a commercial complaint reveals a new design defect or unexpected failure mode, the sponsor must immediately evaluate whether that finding constitutes "significant new information" or a potential UADE that must be reported to the IDE study investigators, reviewing IRBs, and the FDA under 21 CFR 812.40 and 812.150(b)(1).

---

Recommended Reading

Enrichment Strategies for Medical Device Clinical Trials: Patient Selection Guide

Clinical Evidence Regulatory2026-08-14 · 35 min read

Empirical Enforcement Analysis: What Happens When Sponsors Miss the Clock?

To evaluate how regulatory authorities enforce investigational safety reporting in practice, we conducted an empirical, full-text analysis across a comprehensive dataset of 3,643 FDA Warning Letters issued between January 2021 and July 2026 (drawn from FDA's bioresearch monitoring and compliance archives, snapshot dated July 31, 2026).

+----------------------------------------------------------------------------------------------------+
|                      FDA WARNING LETTER ENFORCEMENT SCAN (3,643 LETTERS)                           |
+----------------------------------------------------------------------------------------------------+
|                                                                                                    |
|  [ CORPUS SUMMARY ]                                                                                |
|  - Total FDA Warning Letters Analyzed: 3,643 (Snapshot: July 31, 2026)                             |
|  - Letters Citing 21 CFR Part 812 (Device IDE Regulations): 5                                      |
|  - Letters Citing 21 CFR 812.150 (IDE Reports & Safety Timelines): 1                               |
|                                                                                                    |
|  [ TARGET CASE: UNITED HEALTH PRODUCTS, INC. (CMS 697777, MARCH 24, 2025) ]                        |
|  - Program: Office of Bioresearch Monitoring Inspectorate (OBMI) / CDRH                            |
|  - Inspection Dates: September 23 to October 4, 2024                                               |
|  - Subject: Significant Risk IDE Investigation for HemoStyp Hemostatic Gauze                       |
|  - Primary Violations:                                                                             |
|    1. 21 CFR 812.46(b)(1): Failure to immediately evaluate Unanticipated Adverse Device Effects.  |
|    2. 21 CFR 812.150(b)(1): Failure to report UADE evaluation results to FDA, reviewing IRBs,     |
|       and participating investigators within 10 working days.                                      |
|    3. 21 CFR 812.40 & 812.46(a): Failure to ensure proper monitoring and secure compliance.       |
|                                                                                                    |
+----------------------------------------------------------------------------------------------------+

Teaching Case: United Health Products, Inc. (Warning Letter CMS 697777)

On March 24, 2025, the FDA issued Warning Letter CMS 697777 to United Health Products, Inc., following an inspection conducted by the Office of Bioresearch Monitoring Inspectorate (OBMI) between September 23 and October 4, 2024. The firm was the sponsor of a Significant Risk clinical investigation evaluating a surgical hemostatic device (HemoStyp).

The FDA cited the sponsor for explicit failure to adhere to the statutory safety reporting timelines:

1. Failure to Immediately Evaluate UADEs (21 CFR 812.46(b)(1)): The inspection revealed that when surgical complications and unexpected adverse device effects were reported by clinical trial sites, the sponsor failed to conduct an immediate medical evaluation of the events.
2. Failure to Report Within 10 Working Days (21 CFR 812.150(b)(1)): Because the sponsor failed to perform timely evaluations, it subsequently failed to submit UADE evaluation reports to the FDA, to all reviewing IRBs, and to all participating investigators within the mandatory 10-working-day window.
3. Regulatory Consequence: The failure to manage safety reporting led FDA BIMO inspectors to expand the audit into overall trial monitoring (21 CFR 812.40), culminating in a formal warning letter. Because the inspection was conducted under the BIMO program — which exists to ensure that data and information in IDE and PMA submissions are scientifically valid and accurate — unresolved safety-reporting findings of this kind put the reliability of the pivotal data supporting the marketing application directly at risk.

Methodological Limits: Warning letters represent the extreme tail of regulatory noncompliance rather than general trial operations across the medical device industry. Finding 1 warning letter specifically citing 21 CFR 812.150 across 3,643 letters indicates that FDA BIMO inspections frequently resolve reporting discrepancies via Form FDA 483 inspectional observations before escalating to a Warning Letter. This enforcement case serves as a qualitative teaching example of how safety reporting failures trigger comprehensive compliance actions.

---

SOP Implementation: The 7 Safety Reporting Failure Modes

Clinical operations teams can eliminate safety reporting compliance risk by systematically auditing their standard operating procedures against the seven most common industry failure modes:

+----------------------------------------------------------------------------------------------------+
|                         7 DEADLY SAFETY REPORTING FAILURE MODES                                    |
+----------------------------------------------------------------------------------------------------+
|                                                                                                    |
|  [ FAILURE 1: THE CAUSALITY WAITING GAME ]                                                         |
|  Waiting for the investigator to complete formal causality workup before starting the clock.       |
|  -> FIX: Clock starts upon AWARENESS of the event, not completion of internal deliberations.       |
|                                                                                                    |
|  [ FAILURE 2: THE CEC ADJUDICATION DELAY ]                                                         |
|  Holding safety reports until the Clinical Events Committee (CEC) meets to adjudicate endpoints.   |
|  -> FIX: Regulatory reporting is an immediate safety duty; CEC adjudication is a separate,         |
|     retrospective data-quality process. Never delay 812.150 or Art. 80 clocks for CEC meetings.    |
|                                                                                                    |
|  [ FAILURE 3: THE DEVICE DEFICIENCY BLINDSPOT ]                                                    |
|  Treating device malfunctions as routine engineering tickets without assessing SAE potential.      |
|  -> FIX: Under EU MDR Art. 80(2)(b), any deficiency that COULD HAVE led to an SAE is reportable.   |
|                                                                                                    |
|  [ FAILURE 4: THE CALENDAR VS WORKING DAYS MISMATCH ]                                              |
|  Applying 10 working days to European sites, causing automatic violations of MDCG 7-day limits.     |
|  -> FIX: Harmonize global SOP intake to 24-48 hours calendar time across all geographies.          |
|                                                                                                    |
|  [ FAILURE 5: THE SINGLE-SITE NOTIFICATION ERROR ]                                                 |
|  Notifying only the FDA and the originating site's IRB, forgetting all other investigators.        |
|  -> FIX: Automate distribution of UADE evaluation reports to ALL participating investigators.      |
|                                                                                                    |
|  [ FAILURE 6: OVERLOOKING 5-DAY NON-AE CLOCKS ]                                                    |
|  Missing 21 CFR 812.150 5-day clocks for emergency deviations or consent exceptions.              |
|  -> FIX: Include emergency deviation and consent logs in weekly safety triage reviews.             |
|                                                                                                    |
|  [ FAILURE 7: ASSUMING EUDAMED AUTOMATION ]                                                        |
|  Assuming EU submissions happen automatically via EUDAMED, missing national NCA portals.           |
|  -> FIX: Maintain a country-by-country NCA submission registry using MDCG 2020-10/2 Rev.1 forms.    |
|                                                                                                    |
+----------------------------------------------------------------------------------------------------+

Standardized 4-Step Safety Triage SOP

+----------------------------------------------------------------------------------------------------+
|                      STANDARDIZED 4-STEP SAFETY TRIAGE WORKFLOW                                    |
+----------------------------------------------------------------------------------------------------+
|                                                                                                    |
|  STEP 1: INTAKE & CLOCK INITIATION (Hours 0 - 24)                                                  |
|  - Site notifies sponsor safety desk within 24 hours of awareness.                                 |
|  - Safety specialist logs event, timestamps receipt, and starts US (working) & EU (calendar) clocks.|
|                                                                                                    |
|  STEP 2: MEDICAL ASSESSMENT & TRIAGE (Hours 24 - 48)                                               |
|  - Medical Monitor reviews event description, IB, risk analysis, and CIP.                          |
|  - Determinations made: (1) Is it serious? (2) Is it related/possibly related? (3) Is it anticipated?|
|  - Imminent Risk Flag: If yes, triggers immediate 2-calendar-day EU emergency submission pathway.  |
|                                                                                                    |
|  STEP 3: REGULATORY REPORT DRAFTING & REVIEW (Days 2 - 5)                                          |
|  - US: Draft formal UADE evaluation report detailing clinical findings and protocol impact.        |
|  - EU: Populate MDCG 2020-10/2 Rev.1 Summary Safety Report Form.                                   |
|                                                                                                    |
|  STEP 4: MULTI-CHANNEL DISTRIBUTION & ARCHIVING (Days 5 - 7 / 10)                                  |
|  - EU: Submit to all active Member State NCAs by Day 7 calendar time.                              |
|  - US: Submit to FDA DCC, all reviewing IRBs, and all participating investigators by Day 10 work.  |
|  - Confirm written receipts and file in the Trial Master File (TMF) safety section.               |
|                                                                                                    |
+----------------------------------------------------------------------------------------------------+

---

Frequently Asked Questions (FAQs)

Who reports a UADE to the FDA: the investigator or the sponsor?

The sponsor reports the UADE to the FDA. Under 21 CFR 812.150(a)(1), the clinical investigator reports the UADE to the sponsor and to the reviewing IRB. Under 21 CFR 812.150(b)(1), the sponsor conducts the formal evaluation and submits the evaluation results to the FDA, to all reviewing IRBs, and to all participating investigators within 10 working days of receiving notice.

How is a UADE different from an Unanticipated Problem Involving Risks to Subjects or Others (UPIRTSO)?

A UADE is a specific statutory classification defined under device regulations (21 CFR 812.3(s)) that requires device association, unexpectedness, and seriousness. A UPIRTSO is a broader human subject protection concept governed by 21 CFR Part 56 and 45 CFR Part 46 that encompasses non-medical incidents (e.g., stolen laptop containing unencrypted patient identifiers, dosing error with no clinical harm, or severe logistical disruption). All UADEs are UPIRTSOs, but not all UPIRTSOs are UADEs.

Are the EU deadlines of 2 days and 7 days legally binding?

The numerical deadlines of 2 calendar days (imminent risk) and 7 calendar days (standard reportable events) are codified in MDCG 2020-10/1 Rev.1, which is an EU guidance document rather than statutory law. However, National Competent Authorities (NCAs) across EU Member States interpret and enforce MDCG 2020-10/1 Rev.1 as the operational standard for satisfying MDR Article 80(2)'s requirement to report "without delay." Treating these deadlines as optional creates immediate regulatory enforcement risk.

Do PMCF investigations under Article 74(1) follow Article 80 or postmarket vigilance?

Neither answer is complete on its own. In PMCF studies under Article 74(1) (CE-marked devices used within intended purpose with additional invasive or burdensome procedures), Article 80(5) routes serious adverse events relating to the device through standard postmarket vigilance under Articles 87 to 90, while Article 80(6) routes SAEs with an established causal relationship to the preceding investigational procedure through the Article 80 clinical investigation pathway. PMCF studies using the CE-marked device within its intended purpose without additional procedures sit outside Article 80 altogether, and CE-marked devices used outside their intended purpose (Article 74(2)) follow Article 80 in full.

Does the investigator still have to notify the IRB if the sponsor already did?

Under 21 CFR 812.150(a)(1), the investigator has an independent duty to report UADEs to the reviewing IRB. Footnote 18 of the FDA December 2025 Final Guidance (Investigator Responsibilities — Safety Reporting) states, for IND safety reports, that if a documented agreement specifies the sponsor submits reports to the IRB on the investigator's behalf and the investigator receives confirmation of the submission, FDA would not expect a duplicate investigator copy. The guidance states this in the drug context without an express IDE analog, so device teams should confirm their reviewing IRBs accept sponsor-submitted UADE reports before relying on the same relief.

What is the difference between a UADE (US) and a USADE (ISO 14155 / EU)?

While both terms describe unexpected, serious device-related events, they derive from different legal frameworks:

• UADE (Unanticipated Adverse Device Effect): Defined in U.S. law under 21 CFR 812.3(s), covering serious adverse effects caused by or associated with a device not previously identified in the investigational plan.
• USADE (Unanticipated Serious Adverse Device Effect): Defined in ISO 14155 as a serious adverse device effect which by its nature, incidence, severity, or outcome has not been identified in the current risk assessment. USADE is the internationally recognized nomenclature used throughout European Clinical Investigation Plans.

---

Recommended Reading

Clinical Events Committees (CEC) and Endpoint Adjudication in Medical Device Trials

Clinical Evidence Regulatory2026-08-13 · 26 min read

Key Regulatory Takeaways

1. U.S. Reporting Relies on Working Days: Investigators have ≤ 10 working days to report UADEs to the sponsor and IRB; sponsors have ≤ 10 working days from notice to submit evaluations to FDA, all IRBs, and all investigators (21 CFR 812.150).
2. European Reporting Relies on Calendar Days: Investigators report to sponsors within ≤ 3 calendar days; sponsors report imminent risk events within ≤ 2 calendar days and standard reportable events within ≤ 7 calendar days under MDCG 2020-10/1 Rev.1.
3. EUDAMED CI Module is Pending: EU clinical trial safety reporting currently operates through national competent authority portals using MDCG 2020-10/2 Rev.1 summary reporting forms.
4. Adjudication Never Pauses the Clock: Endpoint adjudication by a Clinical Events Committee (CEC) or review by a Data Monitoring Committee (DMC) does not extend statutory safety reporting windows.
5. Harmonize SOPs to the Strictest Standard: Global clinical trial operations should establish a 24–48 hour site notification threshold and sponsor distribution timelines that default well inside the shortest applicable clock — 2 calendar days for imminent-risk EU events, 7 calendar days otherwise — to remain compliant across FDA, EU MDR, and ISO 14155 requirements simultaneously.